AVA-028

N/A

Report date: 2022/04/28 18:04:32

Base Information

Drug NameAVA-028
Drug Alias NamePD-L1 Affimer®/IL2 bispecific(Avacta)AVA-028
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-2 replacementsAnti-Programmed death-ligand 1
TargetsInterleukin-2Programmed death-ligand 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAvacta Group PLC
China Registration ClassN/A

Develop Information

Active CompaniesLG Chem Life Sciences Innovation Center IncAvacta Group PLC
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A